Hirokazu Shoji

3.3k total citations
154 papers, 1.8k citations indexed

About

Hirokazu Shoji is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hirokazu Shoji has authored 154 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 80 papers in Pulmonary and Respiratory Medicine and 66 papers in Surgery. Recurrent topics in Hirokazu Shoji's work include Gastric Cancer Management and Outcomes (56 papers), Colorectal Cancer Treatments and Studies (29 papers) and Esophageal Cancer Research and Treatment (23 papers). Hirokazu Shoji is often cited by papers focused on Gastric Cancer Management and Outcomes (56 papers), Colorectal Cancer Treatments and Studies (29 papers) and Esophageal Cancer Research and Treatment (23 papers). Hirokazu Shoji collaborates with scholars based in Japan, United States and United Kingdom. Hirokazu Shoji's co-authors include Ken Kato, Atsuo Takashima, Satoru Iwasa, Yoshitaka Honma, Masayuki Ohashi, Kei Watanabe, Narikazu Boku, Natsuko Okita, Keiichi Katsumi and Tetsuya Hamaguchi and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Hirokazu Shoji

139 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hirokazu Shoji Japan 23 815 720 527 350 332 154 1.8k
Takeru Wakatsuki Japan 21 1.1k 1.4× 531 0.7× 714 1.4× 241 0.7× 356 1.1× 159 1.8k
W. Qian United Kingdom 18 703 0.9× 532 0.7× 406 0.8× 289 0.8× 244 0.7× 39 1.8k
Khaldoun Almhanna United States 27 982 1.2× 1.2k 1.6× 1.1k 2.2× 162 0.5× 596 1.8× 168 2.5k
Shinichi Tsutsui Japan 23 982 1.2× 549 0.8× 565 1.1× 174 0.5× 651 2.0× 96 2.0k
Alfonso De Stefano Italy 28 964 1.2× 835 1.2× 1.0k 1.9× 359 1.0× 610 1.8× 97 2.5k
Wenzhuo He China 19 878 1.1× 296 0.4× 279 0.5× 184 0.5× 241 0.7× 84 1.3k
Mizutomo Azuma Japan 25 927 1.1× 810 1.1× 1.2k 2.3× 154 0.4× 420 1.3× 91 2.2k
Boudewijn van Etten Netherlands 22 1.2k 1.4× 943 1.3× 399 0.8× 113 0.3× 168 0.5× 74 1.8k
Ji‐Youn Sung South Korea 21 478 0.6× 355 0.5× 309 0.6× 195 0.6× 400 1.2× 90 1.4k
Yasuyuki Fukai Japan 30 742 0.9× 943 1.3× 701 1.3× 133 0.4× 956 2.9× 74 2.2k

Countries citing papers authored by Hirokazu Shoji

Since Specialization
Citations

This map shows the geographic impact of Hirokazu Shoji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirokazu Shoji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirokazu Shoji more than expected).

Fields of papers citing papers by Hirokazu Shoji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirokazu Shoji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirokazu Shoji. The network helps show where Hirokazu Shoji may publish in the future.

Co-authorship network of co-authors of Hirokazu Shoji

This figure shows the co-authorship network connecting the top 25 collaborators of Hirokazu Shoji. A scholar is included among the top collaborators of Hirokazu Shoji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirokazu Shoji. Hirokazu Shoji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fujii, Hiroyuki, Hirokazu Shoji, Hidekazu Hirano, et al.. (2025). Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis. ESMO Open. 10(1). 104098–104098.
2.
Shoji, Hirokazu, Daisuke Takahari, Akira Ooki, et al.. (2025). Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer. Scientific Reports. 16(1). 692–692.
3.
Yamamoto, Shun, Yoshitaka Honma, Hidekazu Hirano, et al.. (2024). Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin. In Vivo. 38(2). 761–766. 2 indexed citations
4.
Arai, Hiroyuki, Takashi Tsuda, Yu Sunakawa, et al.. (2024). Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID). Cancer Medicine. 13(7). e7107–e7107. 1 indexed citations
5.
Takashima, Atsuo, Kota Ouchi, Takeru Wakatsuki, et al.. (2023). A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.. Journal of Clinical Oncology. 41(4_suppl). 206–206. 1 indexed citations
6.
Boku, Narikazu, Chie Kudo‐Saito, Hirokazu Shoji, et al.. (2023). LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study).. Journal of Clinical Oncology. 41(4_suppl). 425–425. 2 indexed citations
7.
Hirano, Hidekazu, et al.. (2023). Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.. Journal of Clinical Oncology. 41(4_suppl). 322–322. 1 indexed citations
8.
Iwasa, Satoru, Kengo Nagashima, Shun Yamamoto, et al.. (2023). Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab. Cancer Medicine. 12(8). 9322–9331. 2 indexed citations
9.
Shitara, Kohei, Kensei Yamaguchi, Kei Muro, et al.. (2023). Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study. International Journal of Clinical Oncology. 29(1). 27–35. 2 indexed citations
10.
Shoji, Hirokazu, Hidekazu Hirano, Koji Izutsu, et al.. (2021). Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer. Case Reports in Oncology. 14(1). 85–89.
11.
Kobayashi, Shin, Shinichiro Takahashi, Naoki Takahashi, et al.. (2020). Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. Annals of Surgical Oncology. 27(9). 3307–3315. 16 indexed citations
12.
Kudo‐Saito, Chie, Takahiro Miyamoto, Hiroshi Imazeki, et al.. (2020). IL33 Is a Key Driver of Treatment Resistance of Cancer. Cancer Research. 80(10). 1981–1990. 30 indexed citations
13.
Otsuka, Ryo, Satoru Iwasa, Takako Yanai, et al.. (2019). Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer. International Journal of Clinical Oncology. 25(4). 595–601. 5 indexed citations
14.
Mizouchi, Tatsuki, Kei Watanabe, Keiichi Katsumi, et al.. (2019). Quantitative radiographic analysis of foraminal re-stenosis after posterior cervical foraminotomy with laminoplasty. Journal of Clinical Neuroscience. 67. 99–104. 5 indexed citations
15.
Shoji, Hirokazu, Kengo Nagashima, Hiroshi Imazeki, et al.. (2019). Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. ESMO Open. 4(3). e000488–e000488. 37 indexed citations
16.
Ohashi, Masayuki, Tôru Hirano, Kazuhiro Hasegawa, et al.. (2018). En Bloc Spondylectomy for Spinal Metastases: Detailed Oncological Outcomes at a Minimum of 2 Years after Surgery. Asian Spine Journal. 13(2). 296–304. 24 indexed citations
17.
Iwasa, Satoru, Yasuhide Yamada, Yuji Heike, et al.. (2016). Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients. Cancer Science. 107(5). 590–600. 10 indexed citations
18.
Tada, Kohei, Shigehisa Kitano, Hirokazu Shoji, et al.. (2016). Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. Cancer Immunology Research. 4(7). 592–599. 54 indexed citations
19.
Ohashi, Masayuki, Tôru Hirano, Kei Watanabe, et al.. (2016). Hydrogen peroxide modulates neuronal excitability and membrane properties in ventral horn neurons of the rat spinal cord. Neuroscience. 331. 206–220. 21 indexed citations
20.
Okuma, Hitomi Sumiyoshi, Satoru Iwasa, Hirokazu Shoji, et al.. (2014). Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.. PubMed. 34(9). 5037–41. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takeru Wakatsuki Breakdown of academic impact, for papers by W. Qian Breakdown of academic impact, for papers by Khaldoun Almhanna Breakdown of academic impact, for papers by Shinichi Tsutsui Breakdown of academic impact, for papers by Alfonso De Stefano Breakdown of academic impact, for papers by Wenzhuo He Breakdown of academic impact, for papers by Mizutomo Azuma Breakdown of academic impact, for papers by Boudewijn van Etten Breakdown of academic impact, for papers by Ji‐Youn Sung Breakdown of academic impact, for papers by Yasuyuki Fukai
Rankless by CCL
2026